Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

14.86 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,205
Open 14.86
Bid (Size) 14.83 (300)
Ask (Size) 14.95 (100)
Prev. Close 14.86
Today's Range 14.86 - 14.86
52wk Range 1.760 - 15.30
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 2.9% below 52-week high
14.86
1.7652W Low 15.3052W High
1 Week 0.6% below 1-week high
13.521W Low 14.961W High

Iovance Biotherapeutics, Inc. - Common Stock (IOVA) traded between $1.76 and $15.30 over the past 52 weeks and last traded at $14.86, 2.9% below its 52-week high. Over the past week it ranged between $13.52 and $14.96.

Past 12 Months
+4.6%
+45.8%
+171.2%
+301.6%
+489.7%
+540.5%
1W +$0.65
1M +$4.67
3M +$9.38
6M +$11.16
YTD +$12.34
1Y +$12.54

IOVA was +540.5% over the past year, +301.6% over six months, +489.7% year to date, +4.6% in the last week.

12 Months vs Market
IOVA
+540.5%
DIA
+12.3%
SPY
+14.6%
QQQ
+17.3%
IWM
+11.1%

Over the past 12 months IOVA returned +540.5% versus DIA (Dow) +12.3%, SPY (S&P 500) +14.6%, QQQ (Nasdaq 100) +17.3% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.00× 3-mo avg
Today 6,205 3-mo avg 16.6M
1W
10.5M
1M
16.7M
3M
16.6M
6M
16.0M
YTD
15.7M
1Y
15.6M

IOVA most recently traded 6,205 shares against a 3-month average daily volume of 16.6M.

More News

Read More
News headline image
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-09-29: top gainers and losers in today's session. ↗
Via Chartmill
Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump ↗
Via Chartmill
Most active stocks in Tuesday's session ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Iovance Biotherapeutics Stock Was on Fire Today ↗
Via The Motley Fool
News headline image
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains ↗
Via MarketBeat
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance (IOVA) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? ↗
Via The Motley Fool
News headline image
Iovance Biotherapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results ↗
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This Stock Is Up 74% This Year: Is It Too Late to Buy? ↗
Via The Motley Fool
News headline image
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Artificial Intelligence

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 14.86
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 10/20/26 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 4.54B
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.